Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formationWomen’s Health Research Faculty Publications
UMMS AffiliationDepartment of Quantitative Health Sciences
SubjectsAnimals; Antibiotics, Antineoplastic; Antigens, CD; Antigens, CD19; Antigens, CD56; Antigens, Differentiation, B-Lymphocyte; Antigens, Differentiation, T-Lymphocyte; Female; Humans; Immunotoxins; *Indoles; Leucomycins; Lymphoma, B-Cell; Mice; Mice, SCID; Tumor Cells, Cultured
AbstractBis-indolyl-(seco)-1,2,9a-tetrahydrocyclopropa[c]benz[e]indol-4-on e compounds are synthetic analogues of CC-1065 that are highly cytotoxic toward a broad spectrum of tumor cell lines. One of these compounds, called DC1, was conjugated to antibodies via novel cleavable disulfide linkers. Conjugates of DC1 with murine mAbs anti-B4 and N901 directed against tumor-associated antigens CD19 and CD56, respectively, proved to be extremely potent and antigen selective in killing target cells in culture. DC1 conjugates with humanized versions of anti-B4 and N901 antibodies were also constructed and demonstrated to be as cytotoxic and selective as the respective murine antibody conjugates. The anti-B4-DC1 conjugate showed antitumor efficacy in an aggressive metastatic human B-cell lymphoma survival model in SCID mice and completely cured animals hearing large tumors. Anti-B4-DC1 was considerably more effective in this tumor model than doxorubicin, cyclophosphamide, etoposide, or vincristine at their maximum tolerated doses.
Rights and PermissionsCitation: Cancer Res. 1995 Sep 15;55(18):4079-84.
Related ResourcesLink to Article in PubMed
Citation InformationRavi V. J. Chari, Kristin A. Jackel, Lizabeth A. Bourret, Susan M. Derr, et al.. "Enhancement of the selectivity and antitumor efficacy of a CC-1065 analogue through immunoconjugate formation" Vol. 55 Iss. 18 (1995) ISSN: 0008-5472 (Linking)
Available at: http://works.bepress.com/kristin_mattocks/14/